AstraZeneca & Daiichi Sankyo Highlight the P-III (TROPION-Lung01) Study Data of Datopotamab Deruxtecan (Dato-DXd) to Treat Non-Squamous NSCLC at WCLC 2024
Shots:
- The P-III (TROPION-Lung01) study assesses Dato-DXd's (6mg/kg) vs docetaxel (75mg/m2) to treat locally advanced/metastatic NSCLC adults with/without actionable genomic alterations, needing systemic therapy after prior treatment
- OS was 12.9mos. vs 11.8mos. (mOS: 12.9mos. vs 11.8mos.) in the overall population & 14.6mos. vs 12.3mos. in non-squamous NSCLC patients regardless of genomic alterations (mOS: 14.6mos. vs 12.3mos.); no OS improvement observed in squamous NSCLC patients
- In addition, preliminary results from the P-II (NeoCOAST-2) study were also featured at WCLC 2024, showing that neoadjuvant Imfinzi + Dato-DXd and carboplatin achieved a 34.1% pCR rate and a 65.9% mPR rate in early-stage resectable NSCLC
Ref: AstraZeneca | Image: AstraZeneca & Daiichi Sankyo
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
